Capricor recently presented four-year data from its HOPE-2 Open-Label Extension (OLE) study at the 2025 Parent Project Muscular Dystrophy (PPMD) Conference, representing one of the longest-running ...

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy Provided by GlobeNewswire Jun 24, 2025, 6:00:00 AM ...

“With the FDA advisory committee meeting now scheduled, we look forward to the opportunity to present the totality of evidence supporting the approval of deramiocel for the treatment of Duchenne ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

Because nearly all children with Duchenne muscular dystrophy in eastern Massachusetts are referred to the Neuromuscular Clinic at Children's Hospital Boston, we do not believe that these six boys ...

About Duchenne Muscular Dystrophy (DMD) DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart.

Ullrich congenital muscular dystrophy (UCMD), due to mutations in the collagen VI genes, is an autosomal recessive form of CMD, commonly associated with distal joints hyperlaxity and severe course. A ...

Deramiocel is currently in late-stage development for the treatment of Duchenne Muscular Dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ ...

Now in its fifth year, the HOPE-2 OLE study remains ongoing, with participants continuing to be monitored for safety, cardiac function, and upper limb performance. About Duchenne Muscular Dystrophy ...

Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel’s long-term safety profile ...

Duchenne muscular dystrophy (DMD) is caused by an X linked mutation within the dystrophin gene at the Xp21.1 locus 1 and is characterised by degeneration of skeletal and cardiac muscle, leading to ...